Willkie Obtains OxyContin Patent Victory for Amneal

April 13, 2016

Favorable decision affirms that Purdue Pharma patent claims are invalid. 

Willkie client Amneal Pharmaceuticals, LLC scored an important appellate victory on April 8, 2016, when a panel of the U.S. Court of Appeals for the Federal Circuit ruled that the asserted claims of U.S. Patent No. 8,337,888 are invalid for obviousness.  The Federal Circuit issued its ruling just three days after the appeal was argued by IP department chair Thomas Meloro. Willkie was engaged for this appeal following a favorable district court decision against Purdue Pharma.

The appeal was handled by partners Thomas Meloro and Michael Johnson, associate Robert Kofsky, and legal assistant Ashley Moore.